IL221748B - Concentrated protein formulations and uses thereof - Google Patents
Concentrated protein formulations and uses thereofInfo
- Publication number
- IL221748B IL221748B IL221748A IL22174812A IL221748B IL 221748 B IL221748 B IL 221748B IL 221748 A IL221748 A IL 221748A IL 22174812 A IL22174812 A IL 22174812A IL 221748 B IL221748 B IL 221748B
- Authority
- IL
- Israel
- Prior art keywords
- concentrated protein
- protein preparations
- preparations
- concentrated
- protein
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33919110P | 2010-03-01 | 2010-03-01 | |
| PCT/US2011/026647 WO2011109365A2 (en) | 2010-03-01 | 2011-03-01 | Concentrated protein formulations and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL221748B true IL221748B (en) | 2019-09-26 |
Family
ID=44542798
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL221748A IL221748B (en) | 2010-03-01 | 2012-09-02 | Concentrated protein formulations and uses thereof |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US9956165B2 (enExample) |
| EP (1) | EP2542221B8 (enExample) |
| JP (2) | JP5937523B2 (enExample) |
| KR (1) | KR101853981B1 (enExample) |
| CN (2) | CN105521491B (enExample) |
| AU (2) | AU2011223805B2 (enExample) |
| BR (1) | BR112012022223B1 (enExample) |
| CA (1) | CA2794929C (enExample) |
| IL (1) | IL221748B (enExample) |
| MX (1) | MX347504B (enExample) |
| NZ (1) | NZ602685A (enExample) |
| RU (1) | RU2626512C2 (enExample) |
| SG (1) | SG184355A1 (enExample) |
| WO (1) | WO2011109365A2 (enExample) |
| ZA (1) | ZA201207331B (enExample) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140186361A1 (en) | 2012-09-07 | 2014-07-03 | Coherus Biosciences, Inc. | Stable Aqueous Formulations of Adalimumab |
| SG184355A1 (en) * | 2010-03-01 | 2012-11-29 | Progenics Pharm Inc | Concentrated protein formulations and uses thereof |
| KR102049223B1 (ko) | 2010-11-04 | 2019-11-28 | 베링거 인겔하임 인터내셔날 게엠베하 | 항－ｉｌ－２３ 항체 |
| AU2012328524B2 (en) * | 2011-10-28 | 2017-05-18 | Excelse Bio, Inc. | Protein formulations containing amino acids |
| WO2013123114A2 (en) * | 2012-02-16 | 2013-08-22 | Santarus, Inc. | Antibody formulations |
| CN109206516A (zh) | 2012-05-03 | 2019-01-15 | 勃林格殷格翰国际有限公司 | 抗IL-23p19抗体 |
| KR20210021153A (ko) * | 2012-09-20 | 2021-02-24 | 모르포시스 아게 | 류마티스 관절염에 대한 치료 |
| CN104995210A (zh) * | 2012-09-20 | 2015-10-21 | 莫弗系统股份公司 | 类风湿关节炎的治疗 |
| IL312865B2 (en) | 2013-09-11 | 2025-06-01 | Eagle Biologics Inc | Liquid protein formulations containing viscosity-lowering agents |
| US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| PL2946765T3 (pl) | 2014-05-23 | 2017-08-31 | Ares Trading S.A. | Ciekła kompozycja farmaceutyczna |
| EP2946767B1 (en) | 2014-05-23 | 2016-10-05 | Ares Trading S.A. | Liquid pharmaceutical composition |
| EP2946766B1 (en) | 2014-05-23 | 2016-03-02 | Ares Trading S.A. | Liquid pharmaceutical composition |
| US10478498B2 (en) | 2014-06-20 | 2019-11-19 | Reform Biologics, Llc | Excipient compounds for biopolymer formulations |
| US11357857B2 (en) | 2014-06-20 | 2022-06-14 | Comera Life Sciences, Inc. | Excipient compounds for protein processing |
| WO2015196091A1 (en) * | 2014-06-20 | 2015-12-23 | Reform Biologics, Llc | Viscosity-reducing excipient compounds for protein formulations |
| EP3172339A1 (en) | 2014-07-24 | 2017-05-31 | Boehringer Ingelheim International GmbH | Biomarkers useful in the treatment of il-23a related diseases |
| BR112017003252A2 (pt) | 2014-08-20 | 2017-11-28 | Cytodyn Inc | terapia com anticorpos contra hiv como substituto de tratamento |
| CA2959629C (en) | 2014-09-03 | 2023-10-31 | Boehringer Ingelheim International Gmbh | Compound targeting il-23a and tnf-alpha and uses thereof |
| SG11201702614SA (en) | 2014-10-01 | 2017-04-27 | Eagle Biolog Inc | Polysaccharide and nucleic acid formulations containing viscosity-lowering agents |
| US20170247460A1 (en) * | 2014-10-18 | 2017-08-31 | Pfizer Inc. | Anti-il-7r antibody compositions |
| US20180200325A1 (en) | 2014-11-18 | 2018-07-19 | Shionogi & Co., Ltd. | Stabilized peptide composition |
| PE20171094A1 (es) | 2014-12-04 | 2017-08-07 | Janssen Biotech Inc | Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda |
| KR101776879B1 (ko) | 2015-01-19 | 2017-09-08 | 주식회사 녹십자 | 항-egfr 항체를 포함하는 약학 제제 |
| WO2016120753A1 (en) | 2015-01-28 | 2016-08-04 | Pfizer Inc. | Stable aqueous anti- vascular endothelial growth factor (vegf) antibody formulation |
| KR20170120616A (ko) | 2015-02-04 | 2017-10-31 | 베링거 인겔하임 인터내셔날 게엠베하 | 염증성 질환의 치료 방법 |
| EP3053572A1 (en) * | 2015-02-06 | 2016-08-10 | Ares Trading S.A. | Liquid pharmaceutical composition |
| SG11201705484WA (en) * | 2015-02-09 | 2017-08-30 | Ucb Biopharma Sprl | Pharmaceutical formulation |
| EP3081942A1 (en) * | 2015-04-17 | 2016-10-19 | Roche Diagniostics GmbH | Pressure transmission liquid for cellular analyzer, cellular analyzer and method for analyzing a liquid cellular sample |
| CR20170526A (es) | 2015-05-20 | 2018-04-03 | Janssen Biotech Inc | ANTICUERPOS ANTI-CD38 PARA EL TRATAMIENTO DE AMILOIDOSIS DE CADENA LIGERA y OTRAS ENFERMEDADES MALIGNAS HEMATOLÓGICAS POSITIVAS PARA CD38 |
| WO2016210130A1 (en) * | 2015-06-23 | 2016-12-29 | Cytodyn Inc. | Inhibition of ccl5 ligand binding to ccr5 receptor and alteration of ccr5/ccl5 axis signaling in inflammation, cancer, autoimmune, and other conditions |
| US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
| TW201726111A (zh) * | 2015-09-30 | 2017-08-01 | 持田製藥股份有限公司 | 含高濃度抗體之液體製劑 |
| US11229702B1 (en) | 2015-10-28 | 2022-01-25 | Coherus Biosciences, Inc. | High concentration formulations of adalimumab |
| JP7027321B2 (ja) | 2015-11-03 | 2022-03-01 | ヤンセン バイオテツク，インコーポレーテツド | 抗ｃｄ３８抗体の皮下製剤及びその使用 |
| EP3435982A1 (en) | 2016-03-31 | 2019-02-06 | VHsquared Limited | Compositions |
| US11071782B2 (en) | 2016-04-20 | 2021-07-27 | Coherus Biosciences, Inc. | Method of filling a container with no headspace |
| TWI826351B (zh) * | 2016-05-31 | 2023-12-21 | 大陸商鴻運華寧（杭州）生物醫藥有限公司 | Ｒ抗體,其藥物組合物及其應用 |
| WO2018002181A1 (en) | 2016-06-28 | 2018-01-04 | Umc Utrecht Holding B.V. | TREATMENT OF IgE-MEDIATED DISEASES WITH ANTIBODIES THAT SPECIFICALLY BIND CD38 |
| CN109562149A (zh) * | 2016-08-05 | 2019-04-02 | 德国杰特贝林生物制品有限公司 | C1酯酶抑制剂的药物制剂 |
| JP2020509025A (ja) * | 2017-03-01 | 2020-03-26 | メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ | モノクローナル抗体製剤 |
| CA3061279A1 (en) * | 2017-05-16 | 2018-11-22 | Octapharma Ag | C1-esterase inhibitor preparation |
| CN111132663A (zh) * | 2017-08-03 | 2020-05-08 | 爵士制药爱尔兰有限公司 | 包含高浓度核酸的制剂 |
| KR102208378B1 (ko) * | 2017-08-17 | 2021-01-28 | 주식회사 녹십자 | 항-egfr 항체를 포함하는 약학 제제 |
| CN111886249A (zh) | 2017-09-18 | 2020-11-03 | 西托戴恩股份有限公司 | 用于鉴定和治疗适合长期抗-ccr5剂治疗的hiv-1感染患者亚群的筛选方法 |
| US11618787B2 (en) | 2017-10-31 | 2023-04-04 | Janssen Biotech, Inc. | Methods of treating high risk multiple myeloma |
| GB201719447D0 (en) | 2017-11-23 | 2018-01-10 | Ucb Biopharma Sprl | Pharmaceutical composition |
| RS67656B1 (sr) | 2018-05-10 | 2026-02-27 | Regeneron Pharma | Formulacije koje sadrže visoke koncentracije fuzionog proteina vegf receptora |
| PE20212185A1 (es) | 2019-02-18 | 2021-11-11 | Lilly Co Eli | Formulacion de anticuerpos terapeuticos |
| US11730812B2 (en) | 2019-03-08 | 2023-08-22 | Boehringer Ingelheim International Gmbh | Anti-IL-36R antibody formulations |
| WO2020216847A1 (en) * | 2019-04-23 | 2020-10-29 | Sanofi | Stable, low-viscosity antibody formulations and uses thereof |
| TW202535466A (zh) | 2019-09-09 | 2025-09-16 | 德商百靈佳殷格翰國際股份有限公司 | 抗-il-23p19抗體調配物 |
| US11045546B1 (en) | 2020-03-30 | 2021-06-29 | Cytodyn Inc. | Methods of treating coronavirus infection |
| KR20230013037A (ko) * | 2020-04-22 | 2023-01-26 | 키모맙 엘티디. | 항-ccl24 항체를 이용한 치료 방법 |
| AU2021279035A1 (en) * | 2020-05-29 | 2023-02-02 | Aduro Biotech Holding, Europe B.V. | Methods of treating IgA nephropathy with an APRIL binding antibody |
| CN111595658B (zh) * | 2020-06-06 | 2023-11-14 | 宾傲 | 一种提取细胞中蛋白的裂解液及其制备方法 |
| AU2021416156A1 (en) | 2020-12-28 | 2023-06-22 | Bristol-Myers Squibb Company | Methods of treating tumors |
| CN116034985B (zh) * | 2022-12-12 | 2025-09-16 | 武汉呵尔医疗科技发展有限公司 | 一种细胞保护液、hpv e6/e7质控片的制备方法及应用 |
| WO2025089468A1 (ko) * | 2023-10-27 | 2025-05-01 | 주식회사 엔솔바이오사이언스 | 펩타이드 함유 액상제제 및 그 제조방법 |
| CN122097252A (zh) * | 2024-11-28 | 2026-05-29 | 珠海泰诺麦博制药股份有限公司 | 一种包含抗破伤风毒素抗体的制剂 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2226575C (en) | 1995-07-27 | 2011-10-18 | Genentech, Inc. | Stabile isotonic lyophilized protein formulation |
| DE60139944D1 (de) | 2000-10-12 | 2009-10-29 | Genentech Inc | Niederviskose konzentrierte proteinformulierungen |
| US20030138417A1 (en) * | 2001-11-08 | 2003-07-24 | Kaisheva Elizabet A. | Stable liquid pharmaceutical formulation of IgG antibodies |
| JP2005530683A (ja) * | 2001-12-21 | 2005-10-13 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | 第ｖｉｉ因子ポリペプチドの液体組成物 |
| WO2003068260A1 (fr) * | 2002-02-14 | 2003-08-21 | Chugai Seiyaku Kabushiki Kaisha | Produits pharmaceutiques en solution contenant des anticorps |
| US7122185B2 (en) | 2002-02-22 | 2006-10-17 | Progenics Pharmaceuticals, Inc. | Anti-CCR5 antibody |
| EP1478738B1 (en) | 2002-02-22 | 2008-11-12 | Progenics Pharmaceuticals, Inc. | Anti-ccr5 antibody |
| CA2476934C (en) | 2002-02-27 | 2009-06-16 | Immunex Corporation | Stabilized tnfr-fc composition comprising arginine |
| AU2004216298B2 (en) | 2003-02-28 | 2009-04-23 | Chugai Seiyaku Kabushiki Kaisha | Stabilized protein-containing formulations |
| PT1610820E (pt) * | 2003-04-04 | 2010-12-16 | Novartis Ag | Formulações de elevada concentração de anticorpos e proteínas |
| CN103393601A (zh) | 2004-05-12 | 2013-11-20 | 巴克斯特国际公司 | 含有蛋白并在高浓度蛋白下显示可注射性的微球体 |
| US7731948B2 (en) * | 2004-06-01 | 2010-06-08 | Ares Trading S.A. | Stabilized interferon liquid formulations |
| WO2006007412A2 (en) * | 2004-06-16 | 2006-01-19 | Nastech Pharmaceutical Company Inc. | Peptide yy formulations having increased stability and resistance to microbial agents |
| AU2006291005A1 (en) * | 2005-09-12 | 2007-03-22 | Novimmune S.A. | Anti-CD3 antibody formulations |
| US20070135343A1 (en) | 2005-11-01 | 2007-06-14 | Wyeth | Sodium chloride solution for drug reconstitution or dilution |
| JP5405122B2 (ja) | 2005-12-21 | 2014-02-05 | ワイス・エルエルシー | 低粘度のタンパク質製剤およびその用途 |
| US7705132B2 (en) * | 2006-10-20 | 2010-04-27 | Amgen Inc. | Stable polypeptide formulations |
| SG184355A1 (en) * | 2010-03-01 | 2012-11-29 | Progenics Pharm Inc | Concentrated protein formulations and uses thereof |
-
2011
- 2011-03-01 SG SG2012072542A patent/SG184355A1/en unknown
- 2011-03-01 CA CA2794929A patent/CA2794929C/en active Active
- 2011-03-01 KR KR1020127025849A patent/KR101853981B1/ko not_active Expired - Fee Related
- 2011-03-01 US US13/582,243 patent/US9956165B2/en active Active
- 2011-03-01 BR BR112012022223-6A patent/BR112012022223B1/pt active IP Right Grant
- 2011-03-01 EP EP11751179.0A patent/EP2542221B8/en active Active
- 2011-03-01 RU RU2012141655A patent/RU2626512C2/ru active
- 2011-03-01 CN CN201510815109.5A patent/CN105521491B/zh active Active
- 2011-03-01 JP JP2012556165A patent/JP5937523B2/ja active Active
- 2011-03-01 WO PCT/US2011/026647 patent/WO2011109365A2/en not_active Ceased
- 2011-03-01 MX MX2012010114A patent/MX347504B/es active IP Right Grant
- 2011-03-01 NZ NZ602685A patent/NZ602685A/en unknown
- 2011-03-01 AU AU2011223805A patent/AU2011223805B2/en active Active
- 2011-03-01 CN CN201180019594.5A patent/CN102946861B/zh active Active
-
2012
- 2012-09-02 IL IL221748A patent/IL221748B/en active IP Right Grant
- 2012-10-01 ZA ZA2012/07331A patent/ZA201207331B/en unknown
-
2016
- 2016-01-28 AU AU2016200495A patent/AU2016200495B2/en active Active
- 2016-05-11 JP JP2016095589A patent/JP6229007B2/ja active Active
-
2018
- 2018-03-19 US US15/925,255 patent/US11571383B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201207331B (en) | Concentrated protein formulations and uses thereof | |
| IL222961A0 (en) | Novel dna-dinding proteins and uses thereof | |
| ZA201305076B (en) | Substituted 1-benzylccloalkycarboxlic acids and use thereof | |
| IL222027A (en) | Peptides and their use | |
| PL2539326T3 (pl) | Połączone bis-arylem arylotriazolony i ich zastosowanie | |
| PL2605757T3 (pl) | Preparaty oparte na nalbufinie i ich zastosowania | |
| PL2588491T3 (pl) | Nowy peptyd i jego zastosowanie | |
| GB201005625D0 (en) | Immunogenic proteins and compositions | |
| EP2593595A4 (en) | NOVEL PEPTIDES AND USES THEREOF | |
| IL227273A0 (en) | A preparation of fluorocarbon-linked peptides | |
| GB201003333D0 (en) | Immunogenic proteins and compositions | |
| PL2627668T3 (pl) | Peptydy i ich zastosowanie | |
| EP2731634A4 (en) | DISINFECTANT FORMULATIONS AND USES THEREOF | |
| PT2563806E (pt) | Leucolectinas humanas e suas utilizações | |
| IL223269A0 (en) | 2 - iminobiotin formulations and uses thereof | |
| ZA201300194B (en) | Formulations | |
| GB201110193D0 (en) | Formulations | |
| GB201013513D0 (en) | Formulations | |
| ZA201300196B (en) | Formulations | |
| HK1180595A (zh) | 浓缩蛋白制剂及其用途 | |
| HK1175998A (en) | Peptides and their use | |
| GB201018647D0 (en) | Formulations | |
| GB201012589D0 (en) | Formulations | |
| GB201007959D0 (en) | Formulations | |
| GB201008358D0 (en) | Formulations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed |